| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AbbVie Inc. | AL002 - (INVOKE-2) | Alzheimer’s disease | Phase 2 | Data Released | Intravenous | Neurology |
| AbbVie Inc. | CVL-871 | Dementia-related apathy | Phase 2a | Oral | Psychiatric | |
| Abeona Therapeutics Inc. | UX111 - (ABO-102) | Sanfilippo syndrome type A (MPS IIIA) | BLA Filing | Ongoing | Intravenous | Genetic Disorder |
| Abivax SA | Obefazimod - (ABTECT) | Ulcerative colitis | Phase 3 | Data Released | Oral | Gastroenterology |
| Abivax SA | Obefazimod - (ABTECT) | Ulcerative colitis | Phase 3 | Data Released | Oral | Gastroenterology |
| Abivax SA | Obefazimod - (ENHANCE-CD) | Crohn's disease | Phase 2b | Enrollment Initiation | Oral | Gastroenterology |
| Abivax SA | Obefazimod | Ulcerative Colitis | Phase 2 | Ongoing | Oral | Gastroenterology |
| ABVC BioPharma Inc. | ABV-1702 | Myelodysplastic Syndrome (MDS) | Phase 2 | IND Clearance | Intravenous | Hematology |